Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease

Show simple item record Collins, Louise M. Toulouse, André Connor, Thomas J. Nolan, Yvonne M. 2012-11-13T09:34:06Z 2012-11-13T09:34:06Z 2012 2012
dc.identifier.citation Collins L.M., Toulouse A., Connor T.J., Nolan Y.M. (2012) 'Contributions of central and systemic inflammationto the pathophysiology of Parkinson's disease'. Neuropharmacology, 62(7), pp. 2154–2168. en
dc.identifier.volume 62 en
dc.identifier.issued 7 en
dc.identifier.startpage 2154 en
dc.identifier.endpage 2168 en
dc.identifier.issn 0028-3908
dc.identifier.issn 1873-7064
dc.identifier.doi 10.1016/j.neuropharm.2012.01.028
dc.description.abstract Idiopathic Parkinson’s disease (PD) represents a complex interaction between the inherent vulnerability of the nigrostriatal dopaminergic system, a possible genetic predisposition, and exposure to environmental toxins including inflammatory triggers. Evidence now suggests that chronic neuroinflammation is consistently associated with the pathophysiology of PD. Activation of microglia and increased levels of pro-inflammatory mediators such as TNF-alpha,IL-1beta and IL-6, reactive oxygen species and eicosanoids has been reported after post mortem analysis of the substantia nigra from PD patients and in animal models of PD. It is hypothesised that chronically activated microglia secrete high levels of pro-inflammatory mediators which damage neurons and further activate microglia, resulting in a feed forward cycle promoting further inflammation and neurodegeneration. Moreover, nigrostriatal dopaminergic neurons are more vulnerable to pro-inflammatory and oxidative mediators than other cell types because of their low intracellular glutathione concentration. Systemic inflammation has also been suggested to contribute to neurodegeneration in PD, as lymphocyte infiltration has been observed in brains of PD patients and in animal models of PD, substantiating the current theory of a fundamental role of inflammation in neurodegeneration. We will examine the current evidence in the literature which offers insight into the premise that both central and systemic inflammation may contribute to neurodegeneration in PD. We will discuss the emerging possibility of the use of diagnostic tools such as imaging technologies for PD patients. Finally, we will present the immunomodulatory therapeutic strategies that are now under investigation and in clinical trials as potential neuroprotective drugs for PD. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.rights Copyright © 2012, Elsevier. NOTICE: this is the author’s version of a work that was accepted for publication in Neuropharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Neuropharmacology, [62, June 2012] en
dc.subject Parkinson's disease en
dc.subject Neuroinflammation en
dc.subject Systemic inflammation en
dc.subject Microglia en
dc.subject Cytokines en
dc.subject Immunomodulatory therapies en
dc.title Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease en
dc.type Article (peer-reviewed) en
dc.internal.authorurl en
dc.internal.authorcontactother André Toulouse, Department Of Anatomy & Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: en
dc.internal.availability Full text available en 2012-11-07T09:41:19Z
dc.description.version Accepted Version en
dc.internal.rssid 183341484
dc.description.status Peer reviewed en
dc.identifier.journaltitle Neuropharmacology en
dc.internal.copyrightchecked No en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress en

Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement